
    
      165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation
      Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN
      165 by Adults With PKU.

      This study is open only to adults who have been exposed to BMN165 in a previous study.

      Study BMN 165-302 is a four-part, Phase 3 study.

        -  PART 1: Open-label period

        -  PART 2: A Randomized, double-blind, placebo-controlled period of 8 weeks

        -  PART 3: PK (plasma BMN 165) and PD (plasma Phe) assessment.

        -  PART4: A long-term, open-label extension study.
    
  